National Medical Care
This article was originally published in The Gray Sheet
Executive Summary
FDA lifts ban on import of hemodialysis bloodlines manufactured at the W. R. Grace subsidiary's Reynosa, Mexico facility. The ban was rescinded following FDA reinspection of the site "and a commitment by NMC to finish certain studies by May 1994 and, in the interim, to perform additional product final product testing" on an expanded sample base. The firm expects by April 14 to certify its Dublin, Ireland dialyzer facility, also on import alert, clearing the way for reinspection. The NMC facilities were placed on import alert in the summer of 1993 and were cited in a recent consent decree with FDA ("The Gray Sheet" Jan. 24, p. 6)
You may also be interested in...
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.